Company intelligence / Profile preview

Ukko Steka

Palo Alto, California, USAukko-steka.fi ↗

Ownership: Private
Development stage: Commercial

Overview

Ukko is developing a pipeline of therapeutics and engineered foods using an AI-powered protein engineering platform. Its lead program is an investigational therapeutic for peanut allergies, with clinical trials planned or in early stages as of 2024. The company is also developing improved gluten products designed for people with celiac disease and other gluten sensitivities. No published clinical results yet.

Therapeutic areas: GastroenterologyImmunology
Modalities: ProteinBiologic
Industry: Biotech

Partnerships

No major pharma partnerships disclosed as of June 2025; investors include Leaps by Bayer and others

Beyond the preview

Go deeper on Ukko Steka.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ukko Steka.

Explore the full profile